Copeptin plays a variety of roles in the differential diagnosis, risk stratification, and prognostic prediction of patients with CVD, and it exerts additional value in the rapid rule-out of AMI and outcome prediction of heart failure (HF) when used in combination with other conventional cardiac biomarkers. The gene discussed is AVP; the disease is hydrops fetalis.